Brought to you by 
Pharmstandard gets tivozanib rights from Aveo; deal terminated
25 Jul 2016
Executive Summary
Aveo Pharmaceuticals Inc. (also known as Aveo Oncology) granted Pharmstandard OJSC exclusive rights to develop, manufacture, and sell tivozanib in Russia, Ukraine, and the Commonwealth of Independent States (CIS) for all indications excluding ocular conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pharmstandard gets tivozanib rights from Aveo; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice